
Riparin‐B as a Potential Inhibitor of AdeABC Efflux System from Acinetobacter baumannii
2023; Hindawi Publishing Corporation; Volume: 2023; Issue: 1 Linguagem: Inglês
10.1155/2023/1780838
ISSN1741-4288
AutoresPatrícia Virna Sales Leão, Ana Laura da Silva Ferreira, Felipe Araújo de Alcântara Oliveira, Avilnete Belém de Souza Mesquita, José de Sousa Lima Neto, Stanley Juan Chavéz Gutierrez, C.E.S. Nogueira, Natália Martins, Daniel Dias Rufino Arcanjo, Humberto Medeiros Barreto, Josie Haydée Lima Ferreira,
Tópico(s)Bacterial biofilms and quorum sensing
ResumoAcinetobacter baumannii is an important opportunistic pathogen that causes serious health-related infections, especially in intensive care units. The present study aimed to investigate the antimicrobial activity of Riparin-B (Rip-B) alone and in association with norfloxacin against multidrug-resistant clinical isolates of A. baumannii. For this, the minimum inhibitory concentrations were determined by the microdilution method. For the evaluation of resistance-modulating activity, MIC values for antibiotics were determined in the presence or absence of subinhibitory concentrations of Rip-B or chlorpromazine (CPZ). The AdeABC-AdeRS efflux system genes from these isolates were detected by PCR. Docking studies were also carried out to evaluate the interaction of Riparin-B and the AdeABC-AdeRS efflux system. The study was conducted from 2017 to 2019. The results showed that Rip-B showed weak intrinsic activity against the strains tested. On the other hand, Rip-B was able to modulate norfloxacin's response against A. baumannii strains that express efflux pump-mediated resistance. Docking studies provided projections of the interaction between Rip-B and EtBr with the AdeB protein, suggesting that Rip-B acts by competitive inhibition with the drug. Results found by in vitro and in silico assays suggest that Rip-B, in combination with norfloxacin, has the potential to treat infections caused by multidrug-resistant A. baumanni with efflux pump resistance.
Referência(s)